← Leaderboards
Louis Caplan
Beth Israel Deaconess Medical Center
$0
Attributed
$0
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$0 · 2
By mechanism
M01$0 · 2
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Harold Fisher Dvorak$13,877,917
- Thomas N Sato$6,857,527
- Elliot Chaikof$40,570,541
- Robert E Gerszten$34,860,502
- Huiyan Zeng$2,837,132
Others in their field
Top investigators on “Alpha Galactosidase”
- Cheryl Louise Stucky · Medical College Of Wisconsin$4,767,055
- Yu-Teh Li · Tulane University Of Louisiana$3,113,466
- Luc Teyton · Scripps Research Institute, The$2,916,161
- Ervin H Epstein · University Of California San Francisco$2,732,941
- Nancy M. Dahms · Medical College Of Wisconsin$2,662,492
- James Alan Shayman · University Of Michigan At Ann Arbor$2,450,889
Research focus
Alpha GalactosidaseClinical ResearchFabry'S DiseaseHuman SubjectHuman Therapy EvaluationMetabolism Disorder ChemotherapyRecombinant ProteinsVascular EndotheliumKidney PharmacologySkin PharmacologyDrug Screening /EvaluationElectrocardiographyPainHeart PharmacologyQuality Of Life
Grant awards (10)
RECOMB HUMAN ALPHA GALACTOSIDASE IN FABRY DISEASE$0
M01 · FY2002 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE A IN FABRY DISEASE$0
M01 · FY2002 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE IN FABRY DISEASE$0
M01 · FY2001 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE A IN FABRY DISEASE$0
M01 · FY2001 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE IN FABRY DISEASE$0
M01 · FY2000 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE A IN FABRY DISEASE$0
M01 · FY2000 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE IN FABRY DISEASE$0
M01 · FY2000 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE A IN FABRY DISEASE$0
M01 · FY2000 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE A IN FABRY DISEASE$0
M01 · FY2000 · RR
RECOMB HUMAN ALPHA GALACTOSIDASE IN FABRY DISEASE$0
M01 · FY2000 · RR